Cortney Caudill's most recent trade in Halozyme Therapeutics Inc. was a trade of 20,000 Common Stock done at an average price of $33.5 . Disclosure was reported to the exchange on March 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.51 per share. | 09 Mar 2026 | 20,000 | 34,366 (0%) | 0% | 33.5 | 670,200 | Common Stock |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 20,000 | 69,224 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 67.75 per share. | 09 Mar 2026 | 17,900 | 16,466 (0%) | 0% | 67.8 | 1,212,743 | Common Stock |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 67.64 per share. | 09 Mar 2026 | 8,857 | 7,055 (0%) | 0% | 67.6 | 599,087 | Common Stock |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 68.25 per share. | 09 Mar 2026 | 2,100 | 14,366 (0%) | 0% | 68.3 | 143,329 | Common Stock |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.51 per share. | 09 Mar 2026 | 1,546 | 15,912 (0%) | 0% | 33.5 | 51,806 | Common Stock |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 1,546 | 67,678 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2026 | 2,666 | 15,403 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2026 | 2,666 | 7,998 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.98 per share. | 20 Feb 2026 | 1,037 | 14,366 (0%) | 0% | 71.0 | 73,606 | Common Stock |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 14,751 | 14,751 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 14,047 | 14,047 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 13,047 | 13,047 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 2,403 | 13,886 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2025 | 9,326 | 17,000 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2025 | 9,326 | 18,651 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 65.19 per share. | 01 Nov 2025 | 4,263 | 12,737 (0%) | 0% | 65.2 | 277,905 | Common Stock |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2025 | 9,031 | 9,031 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2025 | 3,625 | 3,625 | - | - | Restricted Stock Units |